Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of Helicobacter pylori: Real‐world evidence
Abstract Background and Aim To evaluate the efficacy and safety of minocycline, vonoprazan, amoxicillin, and bismuth quadruple therapy for Helicobacter pylori (H. pylori) treatment. Methods From August 2022 to May 2023, clinical data were collected from patients who received H. pylori eradication tr...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-05-01
|
| Series: | JGH Open |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jgh3.13070 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849715461583798272 |
|---|---|
| author | Qiyunna He Yan Ou Huili Zhu Zhiqian Chen Dailan Yang Qian Cheng Xia Yin Lina Xiao Lin Cai Yan Ye Xin Xu Juan Liao |
| author_facet | Qiyunna He Yan Ou Huili Zhu Zhiqian Chen Dailan Yang Qian Cheng Xia Yin Lina Xiao Lin Cai Yan Ye Xin Xu Juan Liao |
| author_sort | Qiyunna He |
| collection | DOAJ |
| description | Abstract Background and Aim To evaluate the efficacy and safety of minocycline, vonoprazan, amoxicillin, and bismuth quadruple therapy for Helicobacter pylori (H. pylori) treatment. Methods From August 2022 to May 2023, clinical data were collected from patients who received H. pylori eradication treatment at West China Fourth Hospital, Sichuan University. One group received the MVAB regimen (amoxicillin, minocycline, vonoprazan, and colloidal bismuth pectin), while another group received the FOAB regimen (amoxicillin, furazolidone, omeprazole, and colloidal bismuth pectin), both administered for 14 days. Follow‐up assessments of safety and compliance were conducted within 1 week after treatment completion. One and a half months after treatment, the success of eradication was evaluated using the urea breath test. Results For the MVAB regimen as a first‐line treatment, the eradication rate was 90.1% (127/141, 95% CI: 85.1–95.1%) in the ITT analysis and 93.4% (127/136, 95% CI: 89.2–97.6%) in the PP analysis as a first‐line treatment. As a second‐line treatment, the eradication rate was 91.3% (21/23, 95% CI: 78.8–103.8%) in both analyses. For the FOAB regimen as a first‐line treatment, the eradication rate was 98.0% (50/51, 95% CI: 94.1–101.2%) in the ITT analysis and 100% (50/50, 95% CI: 100%) in the PP analysis. As a second‐line treatment, the eradication rate was 100% (6/6, 95% CI: 100%) in both analyses. Moreover, there was no significant difference in the incidence of adverse events between the two groups (MVAB regimen: 5.5% and FOAB regimen: 8.8%; P > 0.05). Conclusions The MVAB regimen could indeed be a viable alternative treatment option to conventional therapies. |
| format | Article |
| id | doaj-art-d7abf6fcbf5a4f19bf12cd82a3d0e311 |
| institution | DOAJ |
| issn | 2397-9070 |
| language | English |
| publishDate | 2024-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | JGH Open |
| spelling | doaj-art-d7abf6fcbf5a4f19bf12cd82a3d0e3112025-08-20T03:13:22ZengWileyJGH Open2397-90702024-05-0185n/an/a10.1002/jgh3.13070Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of Helicobacter pylori: Real‐world evidenceQiyunna He0Yan Ou1Huili Zhu2Zhiqian Chen3Dailan Yang4Qian Cheng5Xia Yin6Lina Xiao7Lin Cai8Yan Ye9Xin Xu10Juan Liao11West China School of Public Health and West China Fourth Hospital Sichuan University Chengdu Sichuan ChinaDepartment of Gastroenterology, West China School of Public Health and West China Fourth Hospital Sichuan University Chengdu ChinaDepartment of Gastroenterology, West China School of Public Health and West China Fourth Hospital Sichuan University Chengdu ChinaDepartment of Gastroenterology, West China School of Public Health and West China Fourth Hospital Sichuan University Chengdu ChinaDepartment of Gastroenterology, West China School of Public Health and West China Fourth Hospital Sichuan University Chengdu ChinaDepartment of Gastroenterology, West China School of Public Health and West China Fourth Hospital Sichuan University Chengdu ChinaDepartment of Gastroenterology, West China School of Public Health and West China Fourth Hospital Sichuan University Chengdu ChinaDepartment of Gastroenterology, West China School of Public Health and West China Fourth Hospital Sichuan University Chengdu ChinaDepartment of Gastroenterology, West China School of Public Health and West China Fourth Hospital Sichuan University Chengdu ChinaDepartment of Gastroenterology, West China School of Public Health and West China Fourth Hospital Sichuan University Chengdu ChinaWest China School of Public Health and West China Fourth Hospital Sichuan University Chengdu Sichuan ChinaDepartment of Gastroenterology, West China School of Public Health and West China Fourth Hospital Sichuan University Chengdu ChinaAbstract Background and Aim To evaluate the efficacy and safety of minocycline, vonoprazan, amoxicillin, and bismuth quadruple therapy for Helicobacter pylori (H. pylori) treatment. Methods From August 2022 to May 2023, clinical data were collected from patients who received H. pylori eradication treatment at West China Fourth Hospital, Sichuan University. One group received the MVAB regimen (amoxicillin, minocycline, vonoprazan, and colloidal bismuth pectin), while another group received the FOAB regimen (amoxicillin, furazolidone, omeprazole, and colloidal bismuth pectin), both administered for 14 days. Follow‐up assessments of safety and compliance were conducted within 1 week after treatment completion. One and a half months after treatment, the success of eradication was evaluated using the urea breath test. Results For the MVAB regimen as a first‐line treatment, the eradication rate was 90.1% (127/141, 95% CI: 85.1–95.1%) in the ITT analysis and 93.4% (127/136, 95% CI: 89.2–97.6%) in the PP analysis as a first‐line treatment. As a second‐line treatment, the eradication rate was 91.3% (21/23, 95% CI: 78.8–103.8%) in both analyses. For the FOAB regimen as a first‐line treatment, the eradication rate was 98.0% (50/51, 95% CI: 94.1–101.2%) in the ITT analysis and 100% (50/50, 95% CI: 100%) in the PP analysis. As a second‐line treatment, the eradication rate was 100% (6/6, 95% CI: 100%) in both analyses. Moreover, there was no significant difference in the incidence of adverse events between the two groups (MVAB regimen: 5.5% and FOAB regimen: 8.8%; P > 0.05). Conclusions The MVAB regimen could indeed be a viable alternative treatment option to conventional therapies.https://doi.org/10.1002/jgh3.13070efficacyeradicationHelicobacter pyloriminocyclinevonoprazan |
| spellingShingle | Qiyunna He Yan Ou Huili Zhu Zhiqian Chen Dailan Yang Qian Cheng Xia Yin Lina Xiao Lin Cai Yan Ye Xin Xu Juan Liao Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of Helicobacter pylori: Real‐world evidence JGH Open efficacy eradication Helicobacter pylori minocycline vonoprazan |
| title | Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of Helicobacter pylori: Real‐world evidence |
| title_full | Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of Helicobacter pylori: Real‐world evidence |
| title_fullStr | Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of Helicobacter pylori: Real‐world evidence |
| title_full_unstemmed | Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of Helicobacter pylori: Real‐world evidence |
| title_short | Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of Helicobacter pylori: Real‐world evidence |
| title_sort | efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of helicobacter pylori real world evidence |
| topic | efficacy eradication Helicobacter pylori minocycline vonoprazan |
| url | https://doi.org/10.1002/jgh3.13070 |
| work_keys_str_mv | AT qiyunnahe efficacyandsafetyofbismuthquadrupleregimenscontainingminocyclineandvonoprazanforeradicationofhelicobacterpylorirealworldevidence AT yanou efficacyandsafetyofbismuthquadrupleregimenscontainingminocyclineandvonoprazanforeradicationofhelicobacterpylorirealworldevidence AT huilizhu efficacyandsafetyofbismuthquadrupleregimenscontainingminocyclineandvonoprazanforeradicationofhelicobacterpylorirealworldevidence AT zhiqianchen efficacyandsafetyofbismuthquadrupleregimenscontainingminocyclineandvonoprazanforeradicationofhelicobacterpylorirealworldevidence AT dailanyang efficacyandsafetyofbismuthquadrupleregimenscontainingminocyclineandvonoprazanforeradicationofhelicobacterpylorirealworldevidence AT qiancheng efficacyandsafetyofbismuthquadrupleregimenscontainingminocyclineandvonoprazanforeradicationofhelicobacterpylorirealworldevidence AT xiayin efficacyandsafetyofbismuthquadrupleregimenscontainingminocyclineandvonoprazanforeradicationofhelicobacterpylorirealworldevidence AT linaxiao efficacyandsafetyofbismuthquadrupleregimenscontainingminocyclineandvonoprazanforeradicationofhelicobacterpylorirealworldevidence AT lincai efficacyandsafetyofbismuthquadrupleregimenscontainingminocyclineandvonoprazanforeradicationofhelicobacterpylorirealworldevidence AT yanye efficacyandsafetyofbismuthquadrupleregimenscontainingminocyclineandvonoprazanforeradicationofhelicobacterpylorirealworldevidence AT xinxu efficacyandsafetyofbismuthquadrupleregimenscontainingminocyclineandvonoprazanforeradicationofhelicobacterpylorirealworldevidence AT juanliao efficacyandsafetyofbismuthquadrupleregimenscontainingminocyclineandvonoprazanforeradicationofhelicobacterpylorirealworldevidence |